olivLaw · US equity research
Cosmos Health Inc. COSM
Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122 · Vertical: Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
Cosmos Health Inc. is a vertically integrated global healthcare group combining drug wholesale, pharmaceutical manufacturing, its own nutraceutical brands and AI-driven drug repurposing research. The company grew revenue in 2025, and in late 2026 it began expanding direct-to-consumer subscription sales in the United States, a segment that could change its profile if the momentum holds.
At the close of 04 Nov 2026, Cosmos Health Inc. (COSM) stock was 0.33 USD (+7.76% on the day), with market capitalisation 33.0 m USD, beta 1.33, 52-week range 0.17–0.73 USD. Latest reported quarter (Q2 2026): revenue of 19.0 m USD (+28.8% YoY), net income of -6.1 m USD, diluted EPS -0.10 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 55.0
- neutral
- Bollinger (20, 2)
- 0.22 – 0.39
- in the upper half of the band · %B 0.62 · band width 56.6%
- SMA 50 / 200
- 0.31 / 0.31
- mixed trend
- MACD (12, 26, 9)
- -0.01 / -0.01
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −5.3% | −1.1% | −4.2 pp | — |
| 3 months | +52.4% | −0.5% | +52.8 pp | — |
| 6 months | −6.9% | +4.4% | −11.3 pp | — |
| Year to date | −34.2% | +12.3% | −46.5 pp | — |
| 1 year | −51.5% | +13.5% | −65.0 pp | +8.1% |
| 3 years | −71.5% | +76.4% | −147.9 pp | +46.5% |
| 5 years | −91.4% | +63.7% | −155.0 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.4 m | 14.2 m | 13.7 m | 14.7 m | 17.1 m | 19.7 m | 17.9 m | 19.0 m |
| Cost of revenue | 11.2 m | 13.2 m | 11.7 m | 13.6 m | 14.5 m | 17.6 m | 16.5 m | 17.5 m |
| Gross profit | 1.2 m | 1.0 m | 2.0 m | 1.2 m | 2.6 m | 2.1 m | 1.4 m | 1.5 m |
| Research & development | 0 | 533.3 k | 15.6 k | 74.6 k | 18.3 k | 410.8 k | 0 | 68.6 k |
| Operating income | -2.2 m | -9.0 m | -833.1 k | -2.6 m | -1.8 m | -11.4 m | -2.2 m | -2.9 m |
| Depreciation & amortisation | 304.1 k | 304.9 k | 315.8 k | 353.9 k | 377.9 k | 315.1 k | 346.5 k | 349.2 k |
| Interest expense | 181.4 k | 319.8 k | 187.1 k | 388.8 k | 669.2 k | 654.8 k | 423.2 k | 602.4 k |
| Pre-tax income | -2.2 m | -9.5 m | -818.1 k | -2.8 m | -5.4 m | -10.1 m | -2.8 m | -6.1 m |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -8.4 m | -3.3 m | -818.1 k | -2.8 m | -5.4 m | -10.1 m | -2.8 m | -6.1 m |
| Diluted EPS | -0.45 | -0.14 ≈ | -0.03 | -0.10 | -0.17 | -0.28 ≈ | -0.06 | -0.10 |
| Operating cash flow | 739.8 k ≈ | -3.8 m | -186.3 k | -1.2 m ≈ | -2.5 m ≈ | -4.6 m | -1.1 m | -1.7 m ≈ |
| Capex | 228.8 k ≈ | 72.5 k | 12.5 k | 22.5 k ≈ | 12.7 k ≈ | 7.9 k | 11.4 k | 63.6 k ≈ |
| Share repurchases | — | 0 | — | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37.1 m | 39.7 m | 55.4 m | 56.2 m | 50.3 m | 53.4 m | 54.4 m | 65.3 m |
| Revenue YoY | +23.6% | +7.0% | +39.6% | +1.5% | −10.5% | +6.0% | +2.0% | +19.9% |
| Net income | -9.1 m | -3.3 m | 820.8 k | -8.0 m | -13.8 m | -18.5 m | -16.2 m | -19.1 m |
| Net income YoY | unavailable | unavailable | unavailable | −1,070.0% | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -0.68 | -0.25 | 0.06 | -23.74 | -33.16 | -2.15 | -1.17 | -0.63 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | −39,666.7% | unavailable | unavailable | unavailable | unavailable |
| net % | -24.4% | -8.3% | 1.5% | -14.2% | -27.5% | -34.7% | -29.7% | -29.3% |
| Free cash flow | -2.1 m | unavailable | -11.6 m | -7.7 m | -14.9 m | -16.9 m | -8.1 m | -8.5 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 715.7 k USD
- Financial debt
- 3.8 m USD
- Net debt
- 3.1 m USD
- Equity
- 18.4 m USD
- Total assets
- 65.5 m USD
- Debt / equity
- 0.20x
- Current ratio
- 1.00x
- ROE
- -89.1%
- ROA
- -32.0%
- FCF margin
- -13.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 55.4 m | 56.2 m | 50.3 m | 53.4 m | 54.4 m | 65.3 m | SEC (XBRL)· 15 Apr 2026verified |
| Cost of revenue | 47.3 m | 47.9 m | 44.4 m | 49.0 m | 50.1 m | 57.4 m | SEC (XBRL)· 15 Apr 2026verified |
| Gross profit | 8.1 m | 8.3 m | 6.0 m | 4.3 m | 4.3 m | 7.9 m | SEC (XBRL)· 15 Apr 2026verified |
| Research & development | — | — | — | 164.9 k | 533.3 k | 519.4 k | SEC (XBRL)· 15 Apr 2026verified |
| Operating income | 2.7 m | -4.5 m | -7.5 m | -21.8 m | -15.5 m | -16.7 m | SEC (XBRL)· 15 Apr 2026verified |
| Depreciation & amortisation | 397.6 k | 352.4 k | 103.2 k | 614.4 k | 1.2 m | 1.4 m | SEC (XBRL)· 15 Apr 2026verified |
| EBITDA | 3.1 m ≈ | -4.2 m ≈ | -7.4 m ≈ | -21.2 m ≈ | -14.3 m ≈ | -15.3 m ≈ | SEC (XBRL)· 15 Apr 2026derived |
| Interest expense | 2.8 m | 2.8 m | 2.3 m | 866.5 k | 1.0 m | 1.9 m | SEC (XBRL)· 15 Apr 2026verified |
| Pre-tax income | 1.2 m | -7.8 m | -13.1 m | -18.5 m | -16.2 m | -19.1 m | SEC (XBRL)· 15 Apr 2026verified |
| Income tax | -377.5 k | 114.0 k | -775.1 k | 0 | 0 | 0 | SEC (XBRL)· 15 Apr 2026verified |
| Net income | 820.8 k | -8.0 m | -13.8 m | -18.5 m | -16.2 m | -19.1 m | SEC (XBRL)· 15 Apr 2026verified |
| Diluted EPS | 0.06 | -23.74 | -33.16 | -2.15 | -1.17 | -0.63 | SEC (XBRL)· 15 Apr 2026verified |
| Weighted average diluted shares | 13.3 m | 656.9 k | 1.9 m | — | 19.1 m | 30.3 m | SEC (XBRL)· 15 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 628.4 k | 286.5 k | 20.7 m | 3.8 m | 315.1 k | 715.7 k | SEC (XBRL)· 15 Apr 2026verified |
| Receivables | — | — | 23.7 m | 19.8 m | 13.5 m | 19.6 m | SEC (XBRL)· 15 Apr 2026verified |
| Inventories | 3.3 m | 3.1 m | 3.5 m | 4.8 m | 4.4 m | 5.8 m | SEC (XBRL)· 15 Apr 2026verified |
| Current assets | 40.8 m | 39.8 m | 56.4 m | 36.6 m | 25.5 m | 38.4 m | SEC (XBRL)· 15 Apr 2026verified |
| Property, plant & equipment, net | 1.8 m | 1.9 m | 1.8 m | 10.3 m | 9.7 m | 10.6 m | SEC (XBRL)· 15 Apr 2026verified |
| Goodwill | 49.7 k | 49.7 k | 49.7 k | 49.7 k | 49.7 k | 49.7 k | SEC (XBRL)· 15 Apr 2026verified |
| Intangibles (excl. goodwill) | 180.8 k | 436.1 k | 657.2 k | 7.8 m | 7.7 m | 7.5 m | SEC (XBRL)· 15 Apr 2026verified |
| Total assets | 43.8 m | 49.4 m | 68.0 m | 66.0 m | 54.3 m | 65.5 m | SEC (XBRL)· 15 Apr 2026verified |
| Accounts payable | 12.0 m | 12.1 m | — | — | 11.2 m | 14.6 m | SEC (XBRL)· 15 Apr 2026verified |
| Short-term debt | — | — | — | 1.9 m | — | — | SEC (XBRL)· 19 Aug 2024verified |
| Long-term debt | 10.8 m | 477.6 k | 5.0 m | 1.3 m | 4.1 m | 3.8 m | SEC (XBRL)· 15 Apr 2026verified |
| Current liabilities | 34.3 m | 29.9 m | 21.7 m | 24.3 m | 25.8 m | 38.3 m | SEC (XBRL)· 15 Apr 2026verified |
| Total liabilities | 48.0 m | 45.0 m | 28.4 m | 30.0 m | 29.8 m | 47.1 m | SEC (XBRL)· 15 Apr 2026verified |
| Equity | -4.2 m † | 4.4 m † | 39.3 m † | 36.0 m | 24.5 m | 18.4 m † | SEC (XBRL)· 15 Apr 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -11.5 m | -7.1 m | -14.9 m | -15.6 m | -7.7 m | -8.4 m | SEC (XBRL)· 15 Apr 2026verified |
| Capex | 117.7 k | 581.4 k | 74.2 k | 1.3 m | 418.1 k | 55.7 k | SEC (XBRL)· 15 Apr 2026verified |
| Free cash flow | -11.6 m ≈ | -7.7 m ≈ | -14.9 m ≈ | -16.9 m ≈ | -8.1 m ≈ | -8.5 m ≈ | SEC (XBRL)· 15 Apr 2026derived |
| Investing cash flow | -117.7 k | -826.8 k | -21.5 k | -13.8 m | -798.3 k | -2.0 m | SEC (XBRL)· 15 Apr 2026verified |
| Financing cash flow | 12.5 m | 7.3 m | 35.0 m | 12.7 m | 5.0 m | 14.1 m | SEC (XBRL)· 15 Apr 2026verified |
| Share repurchases | 200.0 k | 376.9 k | — | 100.5 k | 0 | — | SEC (XBRL)· 15 Apr 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 43.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 33.0 m USD
Key indicators
Coverage and freshness
Score by group
44% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 43.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -58.3% | 0 (on a fixed band) | 24% |
| Net margin · Quality | -33.1% | 25 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 9.0% | 75 (on a fixed band) | 19% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -7.8x | 0 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 1.1x | 21 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -30.1% | 0 (on a fixed band) | 19% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet8/100 · 2/3 factors with a value
- Growth· partial75/100 · 1/2 factors with a value
- Quality9/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
COSMOS HEALTH INC. (COSM). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 65.3 m USD in 2025; YoY growth 19.9%; net margin -33.1%; ROE -104.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 43.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 9.0%
What contradicts it
- ROIC: -58.3%
- Net margin: -33.1%
- Interest coverage: -7.8x
- Current ratio: 1.1x
- FCF yield: -30.1%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122) · same industry (4-digit SIC) · compared with 8 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| MCKMcKESSON CORPORATION | 123.5 bn | 27.5 | — | 1.1% | +12.4% | +21% / +127% |
| CORCencora, Inc. | 67.6 bn | 26.3 | 104.3% | 0.8% | +9.3% | −4% / +74% |
| CAHCardinal Health, Inc. | 60.9 bn | 36.2 | — | 0.7% | +14.2% | +23% / +145% |
| HLFHerbalife Ltd. | 1.6 bn | 9.1 | — | 3.4% | +0.9% | +20% / +19% |
| NUSNu Skin Enterprises, Inc. | 242.9 m | — | -32.5% | -15.7% | −14.3% | −50% / −71% |
| COSMCosmos Health Inc. | 33.0 m | — | -104.0% | -33.1% | +19.9% | −51% / −72% |
| HKPDCellyan Biotechnology Co., Ltd | 30.2 m | — | -0.6% | -0.1% | +21.7% | +87% / unavailable |
| ESYNHwh International Inc. | 11.6 m | — | -88.9% | -680.0% | −30.8% | −4% / −97% |
| MEDSDataMeds AI, Inc. | 4.6 m | — | — | -1,100.3% | +28.7% | −95% / unavailable |
1- and 3-year price returns: for COSM from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Cosmos Health Inc. is a vertically integrated global healthcare group combining drug wholesale, pharmaceutical manufacturing, its own nutraceutical brands and AI-driven drug repurposing research. The company grew revenue in 2025, and in late 2026 it began expanding direct-to-consumer subscription sales in the United States, a segment that could change its profile if the momentum holds.
SWOT
Strengths
- The company has a vertically integrated model from manufacturing to distribution, with GMP and EMA certifications and wholesale licenses in several countries 12.
- Its own nutraceutical brands and the margin expansion in fiscal 2025 point to a favourable shift in revenue mix 1.
- The U.S. direct platform has a recurring subscription base that has grown month to month in recent reports 3.
Weaknesses
- The company reported net losses in fiscal 2024 and 2025 and discloses substantial doubt about its ability to continue as a going concern 12.
- Reliance on Cosmofarm for most revenue and a concentration on European markets limit diversification 1.
- Large provisions were booked against uncollected receivables, including amounts owed by a related party 1.
Opportunities
- Expanding direct U.S. sales and growing the subscription base could build higher recurring revenue 3.
- Developing contract manufacturing and innovative medicines could open new revenue sources 1.
- Expansion into new regions such as the Gulf and Eastern Europe could support distribution of the company's own brands 1.
Risks
- Going concernhigh
The latest quarterly report warns that without additional capital the company may need to cut costs, which could delay product development 2.
- Currency riskmedium
Revenue is mainly in local currencies, so a stronger dollar could reduce the reported value of results 1.
- Pricing and reimbursement rulesmedium
U.S. legislation and European rules on drug prices could limit revenue from certain products 1.
- Uncollected receivableshigh
Provisions recorded for a related party and for advances show that recovery of some amounts could remain uncertain 1.
- Data securitymedium
The company holds personal and payment data of customers, and a cyber attack could lead to financial and reputational losses 1.
Investment thesis
What would need to be true (bull case)
- If revenue from direct U.S. sales keeps growing, the company could diversify its income sources and improve margins.
- The gross margin increase in fiscal 2025 suggests the shift in product mix could become a lasting factor.
- Integrating manufacturing, distribution and own brands gives cost control advantages, if sustained.
What would break the thesis
- Repeated net losses and the going concern warning could force shareholder dilution through new financing.
- Dependence on one subsidiary for most revenue leaves the company exposed to local market changes.
- Rapid subscription growth in the U.S. rests on internal estimates, and actual results could differ materially.
What to watch
- Actual results of direct U.S. sales and the number of active subscriptionsQ4 2026
- Gross margin trends by segment, especially nutraceuticalsQ1 2027
- How receivable and advance provisions affect future results2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Cosmos Health Inc., incorporated in 2009 in Nevada, is a diversified, vertically integrated healthcare group that owns proprietary pharmaceutical and nutraceutical brands, produces and distributes generic medicines, operates a telehealth platform and conducts research into innovative medicines and drug repurposing 1. Its activities span research, manufacturing, marketing and distribution, and its stated strategy is to expand its own portfolio and international distribution networks 1. More than 98% of net sales in 2025 were made outside the United States, although direct U.S. sales began through the Sky Premium Life brand 1.
Segments
Wholesale and pharmaceutical distribution
The subsidiary Cosmofarm S.A. distributes a broad range of prescription and OTC medicines, medical devices and parapharmaceutical products to pharmacies, hospitals and distributors, and represented approximately 90% of total revenues and COGS in fiscal 2025 1. Its gross margin is lower than the company's other business lines, but its volume supports consolidated revenue scale 1.
Market context
The company operates in large, growing markets: the global generic drugs market was valued at $424.98 billion in 2025 with a projected CAGR of 8.35% 1, and the nutraceuticals market was valued at $636.31 billion in 2025, expanding at a CAGR of 7.64% through 2034 1. Oncology and drug repurposing markets are also cited as areas of interest 1.
Trends
- Growing demand for generic medicinestailwind
Patent expirations and demand for cost-effective medicines support growth in the generics segment, which could benefit the company's volumes 1.
- Rising interest in preventive healthtailwind
A shift toward prevention and dietary supplements may support demand for the company's own nutraceutical brands 1.
- Price pressure and regulationheadwind
Price controls and cost containment in European and U.S. healthcare systems could reduce distributor margins and affect future revenue from certain products 1.
- Financing costs and currency movementsmixed
Floating-rate loans and fluctuations in the dollar may affect costs and reported results, since most sales are in euros and other local currencies 12.
Competitive position
The company competes with other wholesale distributors and generic producers, as well as with other nutraceutical brands and OTC products already on the market 1. Competitive pressure is strongest in wholesale distribution, where margins are thin, and in online supplement sales, where entry barriers are low 13.
- Other wholesale drug distributors
Compete for the same pharmacies and hospitals; the sources do not name a directly competing U.S.-listed company.
- Generic drug manufacturers
Compete in the generic medicines portfolio; the company operates in European and Gulf markets.
- Nutraceutical and supplement brands
Compete in online sales and on platforms such as Amazon and Tmall.
- Telemedicine platforms
Compete with the ZipDoctor service in the U.S. subscription telehealth market.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report22 Oct 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report09 Oct 2026Results of operations · Financial statements and exhibits
- Current report20 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report18 Aug 2026
- Current report16 Jul 2026Item 3.03 · Departure or appointment of officers · Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Current report06 Jul 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Proxy statement02 Jun 2026
- Current report22 May 2026Results of operations · Financial statements and exhibits
- Quarterly report20 May 2026
- Current report16 Apr 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Cosmos Health Inc. · 15 Apr 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Cosmos Health Inc. · 18 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Cosmos Health Inc. · 22 Oct 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.